Jin, X.-F.; Spöttl, G.; Maurer, J.; Nölting, S.; Auernhammer, C.J.
Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers 2021, 13, 1485.
https://doi.org/10.3390/cancers13061485
AMA Style
Jin X-F, Spöttl G, Maurer J, Nölting S, Auernhammer CJ.
Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers. 2021; 13(6):1485.
https://doi.org/10.3390/cancers13061485
Chicago/Turabian Style
Jin, Xi-Feng, Gerald Spöttl, Julian Maurer, Svenja Nölting, and Christoph Josef Auernhammer.
2021. "Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro" Cancers 13, no. 6: 1485.
https://doi.org/10.3390/cancers13061485
APA Style
Jin, X.-F., Spöttl, G., Maurer, J., Nölting, S., & Auernhammer, C. J.
(2021). Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers, 13(6), 1485.
https://doi.org/10.3390/cancers13061485